Objective: Amnesic mild cognitive impairment (MCIa) is often characterized as an early stage of Alzheimer's dementia (AD). The latency of the P2, an electroencephalographic component of the flash visual evoked potential (FVEP), is significantly longer in those with AD or MCIa when compared with controls. The present investigation examined the diagnostic accuracy of several FVEP-P2 procedures in distinguishing people with MCIa and controls.
Methods: The latency of the FVEP-P2 was measured in participants exposed to a single flash condition and five double flash conditions. The double flash conditions had different inter-stimulus intervals between the pair of strobe flashes.
Results: Significant group differences were observed in the single flash and two of the double flash conditions. One of the double flash conditions (100 ms) displayed a higher predictive accuracy than the single flash condition, suggesting that this novel procedure may have more diagnostic potential. Participants with MCIa displayed similar P2 latencies across conditions, while controls exhibited a consistent pattern of P2 latency differences. These differences demonstrate that the double stimulation procedure resulted in a measurable refractory effect for controls but not for those with MCIa.
Conclusions: The pattern of P2 group differences suggests that those with MCIa have compromised cholinergic functioning that results in impaired visual processing. Results from the present investigation lend support to the theory that holds MCIa as an intermediate stage between normal healthy aging and the neuropathology present in AD. Measuring the FVEP-P2 during several double stimulation conditions could provide diagnostically useful information about the health of the cholinergic system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/gps.4117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of cold storage on double integrating sphere optical property measurements of porcine dermis and subcutaneous fat from 400 to 1100 nm.
J Biomed Opt
January 2025
Texas A&M University, Department of Biomedical Engineering, College Station, Texas, United States.
Significance: Accurate values of skin optical properties are essential for developing reliable computational models and optimizing optical imaging systems. However, published values show a large variability due to a variety of factors, including differences in sample collection, preparation, experimental methodology, and analysis.
Aim: We aim to explore the influence of storage conditions on the optical properties of the excised skin from 400 to 1100 nm.
Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.
Maturitas
February 2025
Hormone Hamburg, Hamburg, Germany. Electronic address:
Objective: To report patient-reported quality-of-life (QOL) outcomes in the DAYLIGHT study.
Study Design: DAYLIGHT was a phase 3b, randomized, double-blind, 24-week, placebo-controlled study. Participants were women aged ≥40 to ≤65 years with moderate to severe vasomotor symptoms (VMS) considered unsuitable for hormone therapy (HT) (contraindications, caution, stoppers, or averse) randomized 1:1 to placebo or fezolinetant 45 mg once daily.
Ultra-High Dose Rate Helium Ion Beams: Minimizing Brain Tissue Damage while Preserving Tumor Control.
Mol Cancer Ther
December 2024
National Center for Tumor Diseases, Heidelberg, Germany.
Ultra-high dose rate radiotherapy with electrons and protons has shown potential for cancer treatment by effectively targeting tumors while sparing healthy tissues (FLASH effect). This study aimed to investigate the potential FLASH sparing effect of ultra-high-dose rate helium ion irradiation, focusing on acute brain injury and subcutaneous tumor response in a preclinical in vivo setting. Raster-scanned helium ion beams were used to compare the effects of standard dose rate (SDR at 0.
View Article and Find Full Text PDFSafety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.
Adv Ther
December 2024
Astellas Pharma Global Development, Northbrook, IL, USA.
Introduction: This study evaluated the safety and tolerability of fezolinetant in women with vasomotor symptoms (VMS) due to menopause in a pooled analysis of data from three 52-week phase 3 studies (SKYLIGHT 1, 2, and 4).
Methods: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies where women (≥ 40 to ≤ 65 years), with moderate to severe VMS (minimum average ≥ 7 hot flashes/day) were randomized to once-daily placebo, fezolinetant 30 mg or 45 mg. After 12 weeks, those on placebo were re-randomized to fezolinetant 30 mg or 45 mg, while those on fezolinetant continued on their assigned dose for 40 weeks.
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Future Oncol
December 2024
Carolina Urologic Research Center/AUC Urologists, Myrtle Beach, South Carolina.
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!